持久左心室辅助装置桥接患者接受循环死亡供心移植的早期结局
本研究基于UNOS数据库2019至2022年成人循环死亡供心移植数据,比较持久左心室辅助装置(LVAD)桥接组与对照组的早期结局。结果显示两组1年死亡率无差异,但LVAD组急性排斥反应更高,且LVAD为急性排斥的独立预测因素。
要点
- LVAD桥接组与对照组1年死亡率无显著差异(P=.34)。
- LVAD桥接组急性排斥反应发生率更高(26% vs 13%,P<.001)。
- 多因素回归显示LVAD为急性排斥独立预测因素(OR 2.21,95%CI 1.32-3.69,P=.002)。
核心结论
- 持久LVAD桥接的循环死亡供心移植患者1年生存率与对照组相似,但急性排斥风险更高。
研究设计与样本
- 回顾性队列研究,查询UNOS数据库2019至2022年成人循环死亡供心移植,LVAD组160例,对照组311例。
主要发现
- LVAD组更年轻(55 vs 58岁,P<.001),BMI更低(28.3 vs 30.3,P<.001),等待时间更长(112 vs 34天,P<.001),离体时间更长(5.7 vs 4.6小时,P<.001),常温区域灌注更少(31% vs 40%,P=.049)。
- LVAD组92%为UNOS状态3和4,对照组状态2占27%、3占10%、4占30%、6占30%。
- Kaplan-Meier分析显示两组1年死亡率无差异(P=.34)。
- 未调整分析中LVAD组急性排斥更高(26% vs 13%,P<.001)。
- 多因素logistic回归显示LVAD为急性排斥独立预测因素(OR 2.21,95%CI 1.32-3.69,P=.002)。
临床怎么用
- 对LVAD桥接患者行循环死亡供心移植时,应加强早期排斥监测与免疫抑制管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Donation after circulatory death heart transplantation potentially increases donor allografts, especially for patients with lower listing status. We assessed the outcomes of donation after circulatory death heart transplantation in patients bridged with durable left ventricular assist devices. METHODS: The United Network for Organ Sharing database was queried for adult heart transplants using donation after circulatory death donors from 2019 to 2022. Patients were stratified between those with durable left ventricular assist devices and those with intra-aortic balloon pump, inotropic, or no bridging support (control group). Primary outcome was 1-year mortality. Secondary end points were hospital length of stay, stroke, pacemaker implantation, dialysis, and acute rejection before discharge. RESULTS: A total of 160 left ventricular assist device recipients and 311 control recipients met study inclusion criteria. Recipients bridged with left ventricular assist devices were younger (55 vs 58 years, P < .001) with lower body mass index (28.3 vs 30.3, P < .001), longer waitlist times (112 vs 34 days, P < .001), longer out of body times (5.7 vs 4.6 hours, P < .001), and less frequent normothermic regional perfusion (31% vs 40%, P = .049). Patients with left ventricular assist devices commonly underwent transplantation at United Network for Organ Sharing status 3 and 4 (92%), whereas control patients underwent transplantation at status 2 (27%), status 3 (10%), status 4 (30%), or status 6 (30%). Kaplan-Meier analysis showed no difference in 1-year mortality between groups (P = .34). However, acute rejection was higher in the unadjusted left ventricular assist device cohort (26% vs 13%, P < .001). On multivariable logistic regression, left ventricular assist device was an independent predictor of acute rejection (odds ratio, 2.21, 95% CI, 1.32-3.69, P = .002). CONCLUSIONS: Durable left ventricular assist devices may be associated with a higher risk of developing an early inflammatory response in donation after circulatory death heart transplantation; however, 1-year survival was similar between groups.
引用
- Moroi MK, Patel K, Rajesh K, et al. Early outcomes in heart transplantation using donation after circulatory death donors in patients bridged with durable left ventricular assist devices. J Thorac Cardiovasc Surg. 2024. PMID: 39260600. doi:10.1016/j.jtcvs.2024.08.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。